JARDIANCE: payments to doctors
Payments that named JARDIANCE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $90.9M
- Providers
- 165,420
- Transactions
- 1,541,030
- Average per transaction
- $59
The per-transaction average — $59 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 165,420 providers the average total is $550, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $52,023,768 | 57.2% |
| Lilly USA, LLC | $31,812,207 | 35.0% |
| Boehringer Ingelheim International GmbH | $5,407,599 | 5.9% |
| Eli Lilly | $777,863 | 0.9% |
| Boehringer Ingelheim RCV GmbH & Co KG | $182,881 | 0.2% |
| Boehringer Ingelheim (phil.) Inc. | $121,445 | 0.1% |
| Boehringer Ingelheim MENA (scientific Office) Fz-llc | $115,884 | 0.1% |
| Boehringer Ingelheim Singapore Pte. Ltd. | $82,506 | 0.1% |
| Boehringer Ingelheim India Pvt. Ltd. | $59,796 | 0.1% |
| Boehringer Ingelheim South Africa (pty) Ltd | $55,915 | 0.1% |
| Boehringer Ingelheim Norway KS | $42,220 | 0.0% |
| Boehringer Ingelheim Mexico SA De CV | $35,150 | 0.0% |
| Boehringer Ingelheim Hong Kong Ltd. | $30,500 | 0.0% |
| Eli Lilly Export S.A. Puerto Rico Branch | $27,511 | 0.0% |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | $22,965 | 0.0% |